An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease

Clinical and Experimental Immunology

Volumn 156, Issue 3, 2009, Pages 518-527

  Lemmers, A ^a,b   Gustot, T ^a,b   Durnez, A ^c   Evrard, S ^a   Moreno, C ^a,b   Quertinmont, E ^b   Vercruysse, V ^b   Demetter, P ^a   Franchimont, D ^a,b   Le Moine, O ^a,b   Geerts, A ^c   Deviere J ^a,b  

^a ERASME HOSPITAL   (Belgium)

^b Laboratory of Experimental Gastroenterology   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Acute phase response; Cirrhosis; Hepatic stellate cell; Interleukin 6; Sgp130

Indexed keywords

FIBRINOGEN; GLYCOPROTEIN GP 130; HYBRID PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; PROTEIN SGP130; SOLUBLE INTERLEUKIN 6 RECEPTOR; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ADULT; ALCOHOL LIVER DISEASE; ARTICLE; BLOOD LEVEL; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER; LIVER BIOPSY; LIVER CELL CULTURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SIGNAL TRANSDUCTION; TRANS SIGNALLING;

ACUTE-PHASE REACTION; ADULT; BIOLOGICAL MARKERS; CELLS, CULTURED; CYTOKINE RECEPTOR GP130; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; HYPERTENSION, PORTAL; INTERLEUKIN-6; LIVER DISEASES, ALCOHOLIC; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 66149110793     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03916.x     Document Type: Article

References (33)

1. Borzio M, Salerno F, Piantoni L et al. Bacterial infection in patients with advanced cirrhosis: a multicenter prospective study. Dig Liver Dis 2001 33 : 41 8. (Pubitemid 32186174)
2. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004 279 : 48487 90. (Pubitemid 39625721)
3. Kushner I, Jiang SL, Zhang D et al. Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1? Ann NY Acad Sci 1995 762 : 102 7.
4. Le Moine O, Deviere J, Devaster JM et al. Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis. J Hepatol 1994 20 : 819 24. (Pubitemid 24216896)
5. Mackenzie I, Woodhouse J. C-reactive protein concentrations during bacteraemia: a comparison between patients with and without liver dysfunction. Intensive Care Med 2006 32 : 1344 51. (Pubitemid 44267922)
6. Park WB, Lee KD, Lee CS et al. Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. Diagn Microbiol Infect Dis 2005 51 : 227 30. (Pubitemid 40460957)
7. Wuestefeld T, Klein C, Streetz KL et al. Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. Hepatology 2005 42 : 1082 90. (Pubitemid 43112675)
8. Heinrich PC, Behrmann I, Müller-Newen G et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998 334 : 297 314. (Pubitemid 28448572)
9. Luchtefeld M, Schunkert H, Stoll M et al. Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man. J Exp Med 2007 204 : 1935 44. (Pubitemid 47236328)
10. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994 300 : 281 90. (Pubitemid 24167878)
11. Narazaki M, Yasukawa K, Saito T et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993 82 : 1120 6. (Pubitemid 23253984)
12. Carithers RL Jr., Herlong HF, Dielh AM et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989 110 : 685 90.
13. Rössle M, Ochs A, Gülberg V et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascitis. N Engl J Med 2000 342 : 1701 7. (Pubitemid 30354517)
14. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 : 15 20. (Pubitemid 24196485)
15. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 : 1313 21. (Pubitemid 40770284)
16. Stordeur P, Poulin LF, Cracium L et al. Cytokine mRNA quantification by real-time PCR. J Immunol Methods 2002 259 : 55 64. (Pubitemid 33124384)
17. Nakabayashi H, Taketa K, Miyano K et al. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res 1982 42 : 3858 63. (Pubitemid 12054507)
18. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies 2. N Engl J Med 1993 328 : 1828 35. (Pubitemid 23174715)
19. Pinzani M. Novel insights into the biology and physiology of the Ito cell. Pharmacol Ther 1995 66 : 387 412.
20. Caligiuri A, De Franco RS, Romanelli RG et al. Antifibrogenic effects of canrenone, an aldosteronic drug, on human hepatic stellate cells. Gastroenterology 2003 124 : 504 20. (Pubitemid 36169266)
21. Deviere J, Content J, Denys C et al. High interleukin-6 serum levels and increased production by leukocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production. Clin Exp Immunol 1989 77 : 221 5. (Pubitemid 19206491)
22. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor α: a major contributor to the hyper dynamic circulation in prehepatic portal hypertensive rats. Gastroenterology 1995 108 : 761 7.
23. Devière J, Content J, Denys C et al. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 1990 11 : 628 34. (Pubitemid 20151741)
24. Atreya R, Mudter J, Finotto S et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000 6 : 583 8. (Pubitemid 30305911)
25. Nowell MA, Richards PJ, Horiuchi S et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003 171 : 3202 9. (Pubitemid 37093546)
26. Rabe B, Chalaris A, May U et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008 111 : 1021 8.
27. Streetz K, Tacke F, Leifeld L et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology 2003 38 : 218 29. (Pubitemid 36775814)
28. Ramadori G, Christ B. Cytokines and the hepatic acute-phase response. Semin Liver Dis 1999 19 : 141 55. (Pubitemid 29326121)
29. Perrin-Cocon L, Agaugué S, Diaz O et al. Th1 disabled function in response to TLR4 stimulation of monocyte-derived DC from patients chronically infected by hepatitis C virus. PLOS One 2008 3 : e2260.
30. Rao RK, Seth A, Sheth P. Recent advances in alcoholic liver disease. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004 286 : G881 4. (Pubitemid 38715649)
31. Albillos A, de la Hera A, Gonzalez M et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003 37 : 208 17. (Pubitemid 36042162)
32. Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 2005 17 : 27 31. (Pubitemid 40128922)
33. Jostock T, Müllberg J, Özbek S et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001 268 : 160 7. (Pubitemid 32052260)